Last updated: 11/07/2018 19:33:30
A double-blind, placebo-controlled, parallel-group study of a second 100mg oral dose of GR43175C in the acute treatment of a migraine attack and of a further 100mg dose in treating headache recurrence.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A double-blind, placebo-controlled, parallel-group study of a second 100mg oral dose of GR43175C in the acute treatment of a migraine attack and of a further 100mg dose in treating headache recurrence.
Trial description: A double-blind, placebo-controlled, parallel-group study of a second 100mg oral dose of GR43175C in the acute treatment of a migraine attack and of a further 100mg dose in treating headache recurrence.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. the oral sumatriptan international multiple-dose study group. Eur Neurol 1991; 31(5):306-13
Ferrari, M.D. et al., Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurences. Cephalalgia 1994;14:330-8
Medical condition
Migraine Disorders
Product
sumatriptan
Collaborators
Not applicable
Study date(s)
September 1990 to August 1991
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1991-01-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website